Rising income and awareness will drive pharma growth: CII
The Rs 36,000 crore Indian pharmaceutical market is likely to grow at 19.4 per cent on the back of rising health consciousness and increasing affordability of the expanding middle class.
By PTI |
NEW DELHI: The Rs 36,000 crore Indian pharmaceutical market is likely to grow at 19.4 per cent on the back of rising health consciousness and increasing affordability of the expanding middle class coupled with health insurance facilities in the country by 2015, according to a CII study.
The study, 'CII-Interlink paper on growth agenda of pharmaceutical industry in India' has been conducted by Interlink, a business and management consulting firm.
Middle class population, health insurance facilities, unpenetrated markets, marketing efficiencies, generics and brand development are the six key drivers which would push the growth in the domestic pharmaceutical segment.
These drivers together will contribute an estimated 6.64 per cent to the growth of Indian pharmaceutical market which is poised to grow at 19.64 per cent by 2015.
Also, the developments may trigger the pharmaceutical industry to be more focussed to meet the challenges of innovations and pricing pressures, the paper pointed out.
Besides this, a large number of patients who are either untreated or under-treated in the country would lead increased demand for newer and better medicines, the paper said. PTI DSH
The study, 'CII-Interlink paper on growth agenda of pharmaceutical industry in India' has been conducted by Interlink, a business and management consulting firm.
Middle class population, health insurance facilities, unpenetrated markets, marketing efficiencies, generics and brand development are the six key drivers which would push the growth in the domestic pharmaceutical segment.
These drivers together will contribute an estimated 6.64 per cent to the growth of Indian pharmaceutical market which is poised to grow at 19.64 per cent by 2015.
Also, the developments may trigger the pharmaceutical industry to be more focussed to meet the challenges of innovations and pricing pressures, the paper pointed out.
Besides this, a large number of patients who are either untreated or under-treated in the country would lead increased demand for newer and better medicines, the paper said. PTI DSH
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
